Cargando…

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the case of a 32-year-old male patient with refractory B-precursor ALL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Köhnke, Thomas, Krupka, Christina, Tischer, Johanna, Knösel, Thomas, Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599591/ https://www.ncbi.nlm.nih.gov/pubmed/26449653 http://dx.doi.org/10.1186/s13045-015-0213-6

Ejemplares similares

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
por: Meckler, Joshua F., et al.
Publicado: (2023)

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
por: Duell, J, et al.
Publicado: (2017)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
por: Sangsuwannukul, Thanich, et al.
Publicado: (2022)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Targeting CD157 in AML using a novel, Fc-engineered antibody construct
por: Krupka, Christina, et al.
Publicado: (2017)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
por: Riillo, Caterina, et al.
Publicado: (2022)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
por: Myers, Regina M., et al.
Publicado: (2022)

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
por: Köhnke, Thomas, et al.
Publicado: (2022)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
por: Jin, Shenhe, et al.
Publicado: (2023)

Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
por: Hatterer, Eric, et al.
Publicado: (2019)

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
por: Viardot, Andreas, et al.
Publicado: (2020)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
por: Zhong, Liping, et al.
Publicado: (2021)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab
por: Naddafi, Fatemeh, et al.
Publicado: (2019)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
por: Semchenkova, Alexandra, et al.
Publicado: (2022)

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
por: Cheng, Pingyan, et al.
Publicado: (2022)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
por: Herrmann, Ines, et al.
Publicado: (2010)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

PB2442: BLINATUMOMAB REDIRECTS DONOR LYMPHOCYTES AGAINST CD19+ ALL WITHOUT INCREASING THE RISK OF BYSTANDER ALLOREACTIVITY AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION
por: Mancusi, Antonella, et al.
Publicado: (2023)

Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
por: Pandey, Madhu S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_meuj91cigisadmqap6vk8rq1hr